Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Pharmaceuticals: their role in developing societies

W McDermott

    Science (New York, N.Y.)
    |July 11, 1980
    PubMed
    Summary
    This summary is machine-generated.

    Developing new drug development systems, not just drugs, is crucial for addressing major diseases in developing countries. This approach tailors R&D to specific financial and biological needs, improving global health equity.

    Related Concept Videos

    You might also read

    Related Articles

    Articles linked to this work by shared authors, journal, and citation graph.

    Sort by
    Same author

    Self-reported psychological distress following a simulated Not For Resuscitation event: how medical students and interns differ.

    BMJ simulation & technology enhanced learning·2022
    Same author

    Antimicrobial therapy of pulmonary tuberculosis.

    Antibiotics & chemotherapy (Northfield, Ill.)·2014
    Same author

    The Therapy of Miliary and Meningeal Tuberculosis: Review of a Five-Year Experience.

    Transactions of the American Clinical and Climatological Association·2011
    Same author

    The absorption of orally administered penicillin.

    Science (New York, N.Y.)·2010
    Same author

    The absorption, excretion, and destruction of orally administered penicillin.

    The Journal of clinical investigation·2010
    Same author

    Antimicrobial therapy of pulmonary tuberculosis.

    Bulletin of the World Health Organization·2010
    Same journal

    Erratum for the Research Article "Detecting supramolecular organic nanoparticles during heat wave".

    Science (New York, N.Y.)·2026
    Same journal

    Local signals, systemic decline.

    Science (New York, N.Y.)·2026
    Same journal

    The mechanics of liver regeneration.

    Science (New York, N.Y.)·2026
    Same journal

    Computing in a memory with physics.

    Science (New York, N.Y.)·2026
    Same journal

    Retraction.

    Science (New York, N.Y.)·2026
    Same journal

    Making time.

    Science (New York, N.Y.)·2026
    See all related articles

    Area of Science:

    • Global Health
    • Pharmaceutical Research & Development
    • Health Technology Assessment

    Background:

    • Disease control strategies differ significantly between developed and developing nations.
    • Current pharmaceutical industry successes primarily focus on individually delivered treatments, which are less applicable to developing countries' public health challenges.
    • Existing R&D models do not adequately address the unique economic and biological contexts of diseases in developing regions.

    Purpose of the Study:

    • To argue for a paradigm shift in pharmaceutical R&D to better serve developing countries.
    • To highlight the need for new systems, rather than new drugs, to tackle prevalent diseases in low-income nations.
    • To propose an R&D framework tailored to the specific financial and biological realities of developing economies.

    Related Experiment Videos

    Main Methods:

    • Conceptual analysis and argumentation.
    • Review of existing disease control technologies and pharmaceutical R&D models.
    • Comparative assessment of health needs in industrialized versus developing countries.

    Main Results:

    • The dominant R&D model in the pharmaceutical industry is misaligned with the primary health concerns of developing countries.
    • The most significant unmet need is not for novel therapeutics but for innovative R&D systems.
    • A tailored R&D system is essential for developing drugs that are both financially viable and biologically effective for widespread disease control in developing nations.

    Conclusions:

    • The pharmaceutical industry must innovate its R&D systems to effectively address global health disparities.
    • Future drug development for developing countries requires a focus on accessible, group-oriented, and economically feasible solutions.
    • Rethinking the R&D process is paramount to improving the impact of pharmaceutical interventions in economically underdeveloped regions.